At the Forefront of Targeted Cancer Therapies
Developing the next generation of medications for the treatment of cancers and genetic diseases
Active Clinical Development Programs
Bimiralisib’s oral and topical formulations are under clinical development for the treatment of Head and Neck Squamous Cell Carcinoma (oral) and Cutaneous T-Cell Lymphoma (topical).
In addition, PIQUR has several other compounds in preclinical research in oncology, dermatology, CNS disorders and genetic diseases.